In addition to their primary role in glucose regulation, SGLT2 inhibitors have demonstrated cardiovascular benefits which enables a more comprehensive approach to T2DM by using SGLT2 inhibitors. Here, SLC5A2 is linked to type 2 diabetes mellitus.